Compare DRCT & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRCT | JAGX |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 2.2M |
| IPO Year | 2021 | 2014 |
| Metric | DRCT | JAGX |
|---|---|---|
| Price | $2.98 | $2.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $32.00 | ★ $60.00 |
| AVG Volume (30 Days) | 28.7K | ★ 61.1K |
| Earning Date | 05-08-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.42 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $34,694,000.00 | $11,511,000.00 |
| Revenue This Year | $5.42 | $61.58 |
| Revenue Next Year | $9.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.04 | $0.22 |
| 52 Week High | $7.21 | $8.00 |
| Indicator | DRCT | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 47.66 | 42.49 |
| Support Level | $2.73 | $1.74 |
| Resistance Level | $2.98 | $2.43 |
| Average True Range (ATR) | 0.22 | 0.28 |
| MACD | -0.06 | -0.15 |
| Stochastic Oscillator | 33.32 | 2.73 |
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.